ORPHAZYME A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 996 DKK | -2.33% |
|
-5.07% | -25.11% |
| Mar. 27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ORPHAZYME A/S | Bio Therapeutic Drugs | -2.33% | -5.07% | -25.11% | -53.57% | -98.11% | 5.22M |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- ORPHA Stock
- Charts Orphazyme A/S
- Comparison Chart
